MDLive Review
Best for: Insured or employer-covered patients wanting GLP-1s within full primary care
MDLive (an Evernorth/Cigna company) is a large telehealth provider offering urgent care, primary care, dermatology and behavioral health. Anti-obesity GLP-1 medications such as Wegovy and Zepbound can be prescribed at the clinician's discretion during a Primary Care routine visit, not urgent care, and are excluded in Florida, Louisiana, Mississippi and New Jersey. MDLive reaches over 50 million people through health insurance and employer benefits but also allows out-of-pocket direct visits, so cost depends heavily on coverage rather than a single published cash price.
Medium confidence · Last verified 2026-06-04 · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
MDLive is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
MDLive prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
✓ Pros
- •Prescribes FDA-approved branded GLP-1s including Wegovy and Zepbound
- •Covered through insurance and employer benefits for 50M-plus people
- •Board-certified physicians averaging about 15 years of experience
- •Part of Evernorth/Cigna, a large established healthcare organization
- •Offers full primary care, not just a single weight-loss funnel
✗ Cons
- •GLP-1s only at clinician discretion in a Primary Care routine visit
- •Anti-obesity meds not available in FL, LA, MS or NJ
- •Distributed mainly via insurers and employers; cost varies by plan
- •No transparent published monthly cash price for GLP-1 care
Ready to start with MDLive?
See current pricing and start your free consultation.
Sources & methodology
Our MDLive review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
Alternatives to MDLive
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-brand compounded GLP-1 with hormone and performance programs
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with MDLive?
See current pricing and start your free consultation.